Study on the efficacy of Sini San combined with Western medicine in treating elderly patients with refractory gastroesophageal reflux disease and liver-gastric disharmony syndrome, and its effects on cytokines

doi:10.3877/cma.j.issn.2095-2015.2026.05.010

Abstract

Abstract:

Objective

To investigate the efficacy of Sini San combined with conventional Western medicine in treating elderly patients with refractory gastroesophageal reflux disease (GERD) and its effects on cytokines.

Methods

A total of 100 elderly patients with refractory GERD (liver-gastric disharmony syndrome) who were admitted to Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine from February 2024 to November 2025 were selected as the research subjects, they were randomly divided into a control group (receiving conventional Western medicine treatment) and a study group (receiving conventional Western medicine treatment combined with Sini San therapy) according to the random number table method, with 50 cases in each group. The clinical effects, Traditional Chinese Medicine (TCM) syndrome scores, GERD questionnaire (GERDQ) scores, serum cytokines, and esophageal motility indicators were compared between the two groups.

Results

The total effective rate of the study group was higher than that of the control group (P<0.05). The TCM syndrome scores and GERDQ scores of the study group at 4 weeks and 12 weeks after treatment were lower than those of the control group (P<0.05). The vasoactive peptides in the study group were lower than those in the control group, while the gastrin, and motilin were higher than those in the control group (all P<0.05). The lying position and standing position reflux time of the study group were shorter than those of the control group, and the resting pressure of the upper and lower esophageal sphincters was higher than that of the control group (P<0.05).

Conclusion

Sini San combined with conventional Western medicine in the treatment of elderly patients with refractory GERD (liver-stomach disharmony syndrome) can significantly improve clinical efficacy, improve TCM syndromes, regulate the secretion of gastrointestinal-related cytokines.

Key words: Gastroesophageal reflux disease, Liver-stomach disharmony syndrome, Sini San, Efficacy, Cytokines, Elderly

Hongwei Song, Yu Zhang, Shanshan Zhang. Study on the efficacy of Sini San combined with Western medicine in treating elderly patients with refractory gastroesophageal reflux disease and liver-gastric disharmony syndrome, and its effects on cytokines[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2026, 16(05): 452-456.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2026.05.010

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2026/V16/I05/452

Figures/Tables 5

References 22

[1]	Davis TA, Gyawali CP. Refractory Gastroesophageal Reflux Disease: Diagnosis and Management[J]. J Neurogastroenterol Motil, 2024, 30(1): 17-28.
[2]	Snyder DL, Katzka DA. Complex Gastroesophageal Reflux Disease [J]. Gastro Hep Adv, 2022, 1(3): 420-430.
[3]	Nian K, Zhang D. The regulatory effect of proton pump inhibitors combined with triple therapy on gut microbiota, visceral hypersensitivity and gastrointestinal hormone secretion disorders in elderly patients with non erosive gastroesophageal reflux disease[J]. Pak J Pharm Sci, 2025, 38(6): 2250-2263.
[4]	Dohi O, Yasuda T, Takagi T, et al. Alterations in Gut Microbiota and Stool Properties Following Treatment with Potassium-Competitive Acid Blocker and Proton Pump Inhibitor[J]. Dig Dis Sci. 2025, 70(11): 3705-3715.
[5]	贾越博, 刘林, 白光, 等. 基于数据挖掘探讨胃食管反流病中医证型与用药规律分析[J]. 世界中医药, 2022, 17(15): 2121-2126, 2134.
[6]	张卓, 张阳, 谢静怡, 等. 四逆散药理作用研究进展及质量标志物(Q-marker)预测分析[J]. 天津中医药大学学报, 2024, 43(5): 457-463.
[7]	王志一, 黄梓洋, 李自波, 等. 四逆散临床应用及药理机制研究进展[J]. 中华中医药学刊, 2025, 43(9): 91-98.
[8]	李毅, 胡娜, 胡兰贵. 四逆散药理作用及治疗内科疾病的临床应用研究[J]. 辽宁中医杂志, 2024, 51(4): 6-10.
[9]	中华医学会消化病学分会. 2020年中国胃食管反流病专家共识[J]. 中华消化杂志, 2020, 40(10): 649-663.
[10]	赵迎盼, 廖宇, 钟家珮, 等. 胃食管反流病问卷(GerdQ)与反流性疾病问卷(RDQ)的比较研究[J]. 胃肠病学和肝病学杂志, 2015, 24(5): 572-574.
[11]	Naik RD. Overview of Refractory Gastroesophageal Reflux Disease [J]. Gastroenterol Hepatol(N Y), 2022, 18(8): 474-476.
[12]	Ganesh Shashi B, Hafsa SN. Current Advances in Diagnosis, Therapeutics, and Surgical Interventions for the Management of Refractory Gastroesophageal Reflux Disease(GERD): An Update[J]. Cureus, 2024, 16(9): e69001.
[13]	Valdovinos Díaz MA, Amieva-Balmori M, Carmona-Sánchez R, et al. Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociacion Mexicana de Gastroenterologia[J]. Rev Gastroenterol Mex(Engl Ed), 2024, 89(1): 121-143.
[14]	Zuluaga Arbeláez N, Hani A, et al. Approach to refractory gastroesophageal reflux disease[J]. Rev Gastroenterol Peru, 2024, 44(1): 41-51.
[15]	Vayal-Veettil A, Gyawali CP. Diagnosis and Management of Gastroesophageal Reflux Disease: Current Insights[J]. Clin Exp Gastroenterol, 2025, 81(8): 149-162.
[16]	王柏欣, 张雯, 朱立, 等. 从肝论治难治性胃食管反流病的策略[J]. 河北中医药学报, 2022, 37(4): 14-16.
[17]	宋姗姗, 黄博臻, 王亮, 等. 基于方证相应理论探讨四逆散现代临床应用[J]. 中南药学, 2024, 22(11): 3115-3119.
[18]	Yadlapati R. Approach to Management of Refractory Gastroesophageal Reflux Disease[J]. Gastroenterol Hepatol(N Y), 2023, 19(8): 499-502.
[19]	翟建宁, 金小晶, 胡胜红. 四逆散合左金丸加减对肝胃不和证老年难治性胃食管反流病患者的临床疗效[J]. 中成药, 2024, 46(10): 3536-3539.
[20]	李培彩, 唐艳萍. 胃食管反流病中医证候、证素分布特点的文献研究[J]. 辽宁中医杂志, 2020, 47(4): 86-89.
[21]	许雨晴, 赵唯含. 柴胡类方治疗胃食管反流病研究进展[J]. 西部中医药, 2024, 37(12): 102-104.
[22]	Jain M. Esophageal manometry findings in patients with refractory symptoms of gastroesophageal reflux disease[J]. Indian J Gastroenterol, 2022, 41(5): 508-512.

组别	例数	性别[例(%)]		年龄(岁,±s)	病程(年,±s)	体重指数(kg/m²,±s)	吸烟史[例(%)]	饮酒史[例(%)]	合并症[例(%)]
组别	例数	男	女	年龄(岁,±s)	病程(年,±s)	体重指数(kg/m²,±s)	吸烟史[例(%)]	饮酒史[例(%)]	高血压	血脂异常	糖尿病
对照组	50	22(44.00)	28(56.00)	71.01±4.33	3.18±0.44	22.71±1.44	15(30.00)	10(20.00)	21(42.00)	17(34.00)	14(28.00)
研究组	50	26(52.00)	24(48.00)	70.60±4.02	3.07±0.40	22.90±1.27	12(24.00)	12(24.00)	24(48.00)	20(40.00)	16(32.00)
t/χ²值		0.641		0.491	1.308	0.700	0.457	0.233	0.364	0.386	0.191
P值		0.423		0.625	0.194	0.486	0.499	0.629	0.546	0.534	0.663

组别	例数	性别[例(%)]		年龄(岁,±s)	病程(年,±s)	体重指数(kg/m²,±s)	吸烟史[例(%)]	饮酒史[例(%)]	合并症[例(%)]
组别	例数	男	女	年龄(岁,±s)	病程(年,±s)	体重指数(kg/m²,±s)	吸烟史[例(%)]	饮酒史[例(%)]	高血压	血脂异常	糖尿病
对照组	50	22(44.00)	28(56.00)	71.01±4.33	3.18±0.44	22.71±1.44	15(30.00)	10(20.00)	21(42.00)	17(34.00)	14(28.00)
研究组	50	26(52.00)	24(48.00)	70.60±4.02	3.07±0.40	22.90±1.27	12(24.00)	12(24.00)	24(48.00)	20(40.00)	16(32.00)
t/χ²值		0.641		0.491	1.308	0.700	0.457	0.233	0.364	0.386	0.191
P值		0.423		0.625	0.194	0.486	0.499	0.629	0.546	0.534	0.663

组别	例数	临床痊愈	显效	有效	无效	总有效率
对照组	50	7(14.00)	11(22.00)	19(38.00)	13(26.00)	37(74.00)
研究组	50	15(30.00)	24(48.00)	7(14.00)	4(8.00)	46(92.00)

组别	例数	临床痊愈	显效	有效	无效	总有效率
对照组	50	7(14.00)	11(22.00)	19(38.00)	13(26.00)	37(74.00)
研究组	50	15(30.00)	24(48.00)	7(14.00)	4(8.00)	46(92.00)

组别	例数	中医证候积分			GERDQ评分
组别	例数	治疗前	治疗4周	治疗12周	治疗前	治疗4周	治疗12周
对照组	50	23.09±3.28	13.13±1.74^a	6.29±0.81^ab	13.40±2.15	9.11±1.12^a	5.54±0.61^ab
研究组	50	23.64±3.01	10.22±1.29^ac	5.40±0.75^abc	13.92±2.01	7.30±0.89^ac	4.20±0.55^abc
F_组间/P_组间		4.095/0.046			5.102/0.026
F_时间/P_时间		7.193/0.009			8.162/0.005
F_交互/P_交互		6.302/0.014			4.999/0.027

Please choose a citation manager

Content to export